Intermethod differences in results for total PSA, free PSA, and percentage of free PSA

被引:40
作者
Slev, Patricia R. [1 ]
La'ulu, Sonia L. [2 ]
Roberts, William L. [1 ]
机构
[1] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA
[2] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA
关键词
prostate-specific antigen; PSA; free PSA; method comparison;
D O I
10.1309/JYBPMFNUF6EYY9TB
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Serum prostate-specific antigen (PSA) assays differ in calibration and response to different PSA forms. We examined intermethod differences in total PSA (tPSA) and free PSA (fPSA) measurements. We tested 157 samples with tPSA concentrations of 2 to 10 ng/mL (2-10 mu g/L) using 6 PSA/fPSA method pairs and 1 tPSA method: AD VIA Centaur (complexed and total; Siemens Diagnostics, Tarrytown, NY), ARCHITECT i2000(SR) (Abbott Diagnostics, Abbott Park, IL), AxSYM (Abbott Diagnostics), IMMULITE 2000 (Siemens Diagnostics), Modular El 70 (Roche Diagnostics, Indianapolis, IN), UniCel DxI 800 (Beckman Coulter, Brea, CA), and VITROS ECi (tPSA only; Ortho-Clinical Diagnostics, Raritan, NJ). Regression analysis was performed for PSA, fPSA, and percentage of fPSA with the ARCHITECT i2000SR comparison method. Differences between test and comparison methods were estimated at 2.5, 4.0, and 10.0 ng/mL (2.5, 4. 0, and 10.0 mu g/L) for tPSA and 15%, 20%, and 25% for percentage of fPSA. Relative differences were more than 10% at 4.0 ng/mL (4.0 mu g/L) tPSA for the Centaur, IMMULITE, ECi, and DxI methods. At 20% fPSA, the relative difference was more than 10% for all methods except the AxSYM. Additional harmonization is needed for tPSA and fPSA methods.
引用
收藏
页码:952 / 958
页数:7
相关论文
共 23 条
[1]  
*BAY HEALTHC, 2007, ADVIA CENT PSA REV K
[2]   SELECTION OF OPTIMAL PROSTATE-SPECIFIC ANTIGEN CUTOFFS FOR EARLY DETECTION OF PROSTATE-CANCER - RECEIVER OPERATING CHARACTERISTIC CURVES [J].
CATALONA, WJ ;
HUDSON, MA ;
SCARDINO, PT ;
RICHIE, JP ;
AHMANN, FR ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 152 (06) :2037-2042
[3]   Viewpoint: Expanding prostate cancer screening [J].
Catalona, WJ ;
Loeb, S ;
Han, M .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (06) :441-443
[4]   Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547
[5]  
Crawford ED, 1999, PROSTATE, V38, P296
[6]   Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: A prospective evaluation [J].
Gann, PH ;
Ma, J ;
Catalona, WJ ;
Stampfer, MJ .
JOURNAL OF UROLOGY, 2002, 167 (06) :2427-2434
[7]   Viewpoint: Limiting prostate cancer screening [J].
Hoffman, RM .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (06) :438-440
[8]   Cancer statistics, 2007 [J].
Jemal, Ahmedin ;
Siegel, Rebecca ;
Ward, Elizabeth ;
Murray, Taylor ;
Xu, Jiaquan ;
Thun, Michael J. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66
[9]   Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation [J].
Kort, Sheila A. R. ;
Martens, Frans ;
Vanpoucke, Hilde ;
van Duijnhoven, Hans L. ;
Blankenstein, Marinus A. .
CLINICAL CHEMISTRY, 2006, 52 (08) :1568-1574
[10]  
LANDIS JR, 1977, BIOMETRICS, V33, P174